Literature DB >> 35309962

Development of Dual Receptor Enhanced Pre-Targeting Strategy-A Novel Promising Technology for Immuno-Positron Emission Tomography Imaging.

Lingyi Sun1, Yongkang Gai2, Zhonghan Li3, Xiaohui Zhang2, Jianchun Li2, Yongyong Ma2, Huiqiang Li2, Ramon J Barajas4, Dexing Zeng5.   

Abstract

PET imaging has become an important diagnostic tool in the era of precise medicine. Various pre-targeting systems have been reported to address limitations associated with traditional immuno-PET. However, the application of these mono-receptor based pre-targeting (MRPT) strategies is limited to non-internalizable antibodies, and the tumor uptake is usually much lower than that in the corresponding immuno-PET. To circumvent these limitations, we develop the first Dual-Receptor Pre-Targeting (DRPT) system through entrapping the tumor-receptor-specific radioligand by the pre-administered antibody. Besides the similar ligation pathway happens in MRPT, incorporation of a tumor-receptor-specific peptide into the radioligand in DRPT enhances both concentration and retention of the radioligand on tumor, promoting its ligation with pre-administered mAb on cell-surface and/or internalized into tumor-cells. In this study, 64Cu based DRPT shows superior performance over corresponding MRPT and immuno-PET using internalizable antibodies. Besides, the compatibility of DRPT with short-lived and generator-produced 68Ga is demonstrated, leveraging its advantage in reducing radio-dose exposure. Furthermore, the feasibility of reducing the amount of the pre-administered antibody is confirmed, indicating the cost saving potential of DRPT. In summary, synergizing advantages of dual-receptor targeting and pre-targeting, we expect that this DRPT strategy can become a breakthrough technology in the field of antibody-based molecular imaging.

Entities:  

Keywords:  EGFR; PET imaging; dual-receptor targeting; integrin αVβ3; pre-targeting

Year:  2021        PMID: 35309962      PMCID: PMC8932640          DOI: 10.1002/adtp.202100110

Source DB:  PubMed          Journal:  Adv Ther (Weinh)        ISSN: 2366-3987


  46 in total

1.  In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

Authors:  Christel Larbouret; Nadège Gaborit; Thierry Chardès; Mickaël Coelho; Emmanuelle Campigna; Caroline Bascoul-Mollevi; Jean-Pierre Mach; David Azria; Bruno Robert; André Pèlegrin
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

2.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

3.  Increasing the efficacy of bioorthogonal click reactions for bioconjugation: a comparative study.

Authors:  Christen Besanceney-Webler; Hao Jiang; Tianqing Zheng; Lei Feng; David Soriano del Amo; Wei Wang; Liana M Klivansky; Florence L Marlow; Yi Liu; Peng Wu
Journal:  Angew Chem Int Ed Engl       Date:  2011-07-14       Impact factor: 15.336

Review 4.  Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology.

Authors:  Sara Sheikhbahaei; Esther Mena; Puskar Pattanayak; Mehdi Taghipour; Lilja B Solnes; Rathan M Subramaniam
Journal:  PET Clin       Date:  2016-10-05

Review 5.  Unconventional nuclides for radiopharmaceuticals.

Authors:  Jason P Holland; Matthew J Williamson; Jason S Lewis
Journal:  Mol Imaging       Date:  2010-02       Impact factor: 4.488

6.  Selective labeling of living cells by a photo-triggered click reaction.

Authors:  Andrei A Poloukhtine; Ngalle Eric Mbua; Margreet A Wolfert; Geert-Jan Boons; Vladimir V Popik
Journal:  J Am Chem Soc       Date:  2009-11-04       Impact factor: 15.419

7.  Photochemical generation of oxa-dibenzocyclooctyne (ODIBO) for metal-free click ligations.

Authors:  Christopher D McNitt; Vladimir V Popik
Journal:  Org Biomol Chem       Date:  2012-10-03       Impact factor: 3.876

8.  Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells.

Authors:  Kelly M Kitchens; Rohit B Kolhatkar; Peter W Swaan; Hamidreza Ghandehari
Journal:  Mol Pharm       Date:  2008-01-04       Impact factor: 4.939

Review 9.  Novel radiolabeled antibody conjugates.

Authors:  D M Goldenberg; R M Sharkey
Journal:  Oncogene       Date:  2007-05-28       Impact factor: 9.867

10.  Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies.

Authors:  A Diaz Miqueli; J Rolff; M Lemm; I Fichtner; R Perez; E Montero
Journal:  Br J Cancer       Date:  2009-03-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.